Lightnews — Scholar-powered news

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 18

Lastly, the biggest thanks go to my mentor
@majorajay.bsky.social
, whose passion for PROs and quality of life investigation is incredibly inspiring. Thank you as well to everyone involved at The University of Chicago and @accordsresearch.bsky.social ! /end
bit.ly/3P4R0sy
#ASH24 #lymsm

1 3

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 18

Thank you for tuning in! This is a mid-study analysis, and we aim to enroll 75 patients before final analysis. We welcome any feedback and impressions from this study as enrollment continues! /14
bit.ly/3P4R0sy

Financial Toxicity, Health-Related Quality of Life, and Medication Adherence Patient-Reported Outcomes (PROs) in Patients with Chronic Lymphocytic Leukemia (CLL) on First-Line Oral Oncolytics

Disclosures. Major:Roche/Genentech: Consultancy; Incyte: Research Funding.

bit.ly

1 1

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 18

This data also helps us counsel our pts before starting OOT. For example, looking back at HRQOL data, you can see that median FACT-LEU scores dipped at 3 months but increased to > baseline scores at 6 months. Pts might expect worse HRQOL initially, but it should get better! /13

1 1

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 18

Patients are at risk for FT regardless of out-of-pocket cost (no correlation between COST score and $0 copay), and qualitative data suggests that the uncertainty of future financial support for these often lifetime therapies drives FT /12

1 1

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 18

What does all of this mean and why is it important to clinicians?
- Patients on 1st line oral oncolytics for CLL are at risk for early and progressive FT AND suboptimal med adherence
- Patients in this group that experience FT are also likely to have worse HRQOL
/11

1 1

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 18

Take-aways from our qualitative analysis:
- Fear of losing financial assistance was very prevalent
- No one reported intentionally missing medications, but a few pts reported rare unintentional missed dose /10

1 2

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 18

Now let's look at how they all relate:
- FACIT-COST positively correlated with FACT-LEU score @ all time points
- FACIT-COST positively correlated with PROMIS-PMAS @ baseline
- Social wellbeing positively correlated with PMAS and MARS scores /9

1 1

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 18

The differences between FACT-LEU total median scores over time did not meet the minimally important difference threshold. When we looked at the components of FACT-LEU, emotional well-being and functional well-being had the lowest median scores at all timepoints. /8

1 1

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 18

PRO data for adherence similarly demonstrated increased suboptimal adherence behaviors over time. Interestingly, the MARS-5 and PROMIS-PMAS instruments tracked in the same direction, but were discrepant in the incidence of suboptimal adherence they caught. /7

1 1

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 18

In our PRO analysis, there was already a significant incidence of FT at baseline (22%), which increased over time. /6

1 1

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 18

47 patients completed PRO instruments at baseline. Longitudinal completion rates remained high (85% 3 mo, 83% 6mo).
- Median age 66, 53% male, 89% white
- 47% medicare, 45% private insurance
- 53% concurrent obinutuzumab
- 66% had $0 copay, 57% grant or PAP support
#ASH24
/5

1 1

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 18

To further validate these PRO instruments for CLL, we also conducted semi-structured interviews and used thematic analysis to assess concordance and discordance with PRO results. /4

1 1

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 18

The PROs we used to measure these variables were FACIT-COST for FT, FACT-LEU for health-related quality of life (HRQOL), and PROMIS-PMAS and MARS-5 for adherence. We measured at time of trial enrollment, 3 months, and 6 months /3

1 1

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 18

Why? Oral oncolytic therapy (OOT) is expensive! Out-of-pocket costs for patients with CLL are predicted to increase 520% by 2025. Additionally, financial toxicity (FT) has been associated with poor health-related quality of life and suboptimal adherence in other malignancies /2

1 2

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 18

Oral agents have changed the CLL treatment landscape. But how does their cost affect patients? Here's a review of our #ASH24 abstract on the relationship between financial toxicity, medication adherence, and health-related QOL in CLL pts on 1L oral therapy #lymsm 🧵/1
@majorajay.bsky.social

1 3

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 14

First pie baked at altitude… cherry pie a la Sally’s Baking Addiction using the Betty Crocker pie crust recipe! Presentation could use work but overall a success

2

Reposted by Jessica Allen MD

Krishna Komanduri @drkomanduri.bsky.social · Dec 8

Lee, et al. from Stanford present results in 24 octogenarians treated with CD19 CAR-T cells.

Overall, higher ICANS rate and much longer LOS (30d vs. 16d) v. age 65-79. Long LOS driven by toxicity.

Similar overall PFS, outcomes suggest safety/efficacy in selected patients. #ASH24 #immunotherapy

1 9

Reposted by Jessica Allen MD

Shematologist, MD @shematologist.medsky.social · Dec 8

Staggering statistics at #ASH24 #TreatingFairly

Patients with cancer who go bankrupt are nearly 80% more likely to die regardless of disease status.

Our system quite literally kills people.

Slide on financial toxicity of cancer care

22 200 520

Reposted by Jessica Allen MD

Ajay Major, MD, MBA @majorajay.bsky.social · Dec 8

Can't congratulate Dr. Allen enough on her #ASH24 abstract; keep your eyes peeled for a manuscript in 2025! And the whole @cuanschutz.bsky.social internal med gang showed up, too! #ASHKudos #lymsm cc @jessicaallenmd.bsky.social @vpizzuti.bsky.social

1 4 12

Reposted by Jessica Allen MD

Ajay Major, MD, MBA @majorajay.bsky.social · Dec 7

Preview of my mentee Dr. Allen's (@jessicaallenmd.bsky.social) study at tonight's #ASH24 poster session. Patient-reported financial toxicity and suboptimal adherence is already substantial in the first few months of initiation of first-line oral oncolytics for CLL, and affects HRQOL. #lymsm #leusm

1 5

Reposted by Jessica Allen MD

Ajay Major, MD, MBA @majorajay.bsky.social · Dec 7

For #ASH24 goers, please check out our #lymsm PRO abstracts:
- Saturday PM: @jessicaallenmd.bsky.social presenting FT & adherence in 1L CLL oral oncolytics
- Monday PM: Dr. Pizzuti presenting heatmap modeling of longitudinal PROs from our BISON-PRO registry (bison-pro.org)

1 6

Reposted by Jessica Allen MD

CU Anschutz Division of Hematology @cuhematology.bsky.social · Dec 6

CU soon in San Diego for a fabulous weekend!! #ASH24

Kicking off for the University of Colorado team today is
Dr. Manali Kamdar.

For more CU team weekend activities: bit.ly/CUHematology...

#HemeOnc #Hematology #BloodSky

3 5

Jessica Allen MD @jessicaallenmd.bsky.social · Dec 7

So excited to attend my first ASH! #ASH24
@ash-hematology.bsky.social

2 7